Statements (57)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:monoclonal_antibody
|
gptkbp:brand |
gptkb:Leqembi
|
gptkbp:chemical_formula |
C6484 H10080 N1716 O2016 S44
|
gptkbp:clinical_trial |
gptkb:Clarity_AD
Phase 3 improved cognitive function safety profile established multiple sites worldwide reduced amyloid levels |
gptkbp:collaboration |
academic institutions
research organizations |
gptkbp:developed_by |
gptkb:Biogen
gptkb:Eisai |
gptkbp:dosage_form |
solution for infusion
|
gptkbp:effective_date |
FDA approved
January 2023 |
gptkbp:funding |
public and private sectors
|
https://www.w3.org/2000/01/rdf-schema#label |
Lecanemab
|
gptkbp:indication |
early Alzheimer's disease
|
gptkbp:invention |
patented
|
gptkbp:is_tested_for |
Phase 1
Phase 2 |
gptkbp:launch_date |
gptkb:2023
|
gptkbp:marketed_as |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
gptkbp:mechanism_of_action |
reduces amyloid plaques
|
gptkbp:patient_population |
older adults
individuals with early-stage Alzheimer's disease |
gptkbp:provides_guidance_on |
Alzheimer's treatment guidelines
|
gptkbp:regulatory_compliance |
conditional approval
|
gptkbp:research |
biological therapy
|
gptkbp:research_areas |
gptkb:neurodegenerative_diseases
|
gptkbp:research_focus |
Alzheimer's disease treatment
disease-modifying therapies biomarker development |
gptkbp:route_of_administration |
intravenous
|
gptkbp:side_effect |
dizziness
fatigue headache nausea confusion infusion-related reactions visual disturbances increased risk of falls cerebral edema cerebral microhemorrhage |
gptkbp:sponsor |
gptkb:Biogen
gptkb:Eisai |
gptkbp:target_audience |
patients with mild Alzheimer's disease
patients with mild cognitive impairment |
gptkbp:targets |
amyloid beta
|
gptkbp:used_for |
gptkb:neurodegenerative_diseases
|
gptkbp:weight |
146 k Da
|
gptkbp:bfsParent |
gptkb:Biogen_Idec
gptkb:Aducanumab |
gptkbp:bfsLayer |
5
|